Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Analyst Comments: Garmin, Acergy, PeopleSupport, Calgon Carbon, Weatherford, Scientific Games, Philip Morris, Cleveland Bio
Sep 30, 2008 08:47 AM
- Analyst Comments: Nat'l Oilwell Varco, Focus Media, Cleveland BioLabs, Nippon Telegraph, Oplink, Citi Trends
Aug 22, 2008 08:44 AM
- Analyst Comments: Logitech, Polycom, Cleveland BioLabs, Stryker, Wilmington
Jul 18, 2008 05:23 PM
- Analyst Comments: Dollar Financial, Cleveland BioLabs, Methanex, Gerdau S.A., Broadcom, Mylan, PALM
May 20, 2008 06:24 PM
- Jobs Report
Jan 04, 2008 10:29 AM
- Cleveland BioLabs Announces Appointment of International Expert in Chemical, Biological and Radiological/Nuclear Threat Countermeasures as Senior Vice President of Public Health and Government Services
Dec 01, 2008 08:22 AM
- Zacks Bull and Bear of the Day Highlights: Inter Parfums, JC Penney, Cleveland BioLabs, O2Micro International and Honda
Nov 18, 2008 07:12 AM
- Zacks Bull and Bear of the Day Highlights: Inter Parfums, JC Penney,Cleveland BioLabs, O2Micro International and Honda
Nov 18, 2008 01:22 AM
- Cleveland BioLabs to Present at Rodman and Renshaw 10th Annual Healthcare Conference
Nov 03, 2008 08:30 AM
- Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction of Myelosuppression in Mouse Model of Chemotherapy
Oct 27, 2008 08:30 AM
- Cleveland BioLabs Receives Letter From NASDAQ Citing Non-Compliance With Global Market Listing Requirements
Oct 24, 2008 05:27 PM
- Cleveland BioLabs to Present at 2008 BIO Investor Forum
Oct 21, 2008 08:30 AM
- Cleveland BioLabs Doses First Healthy Volunteer in Initial Safety Study for Protectan CBLB502
Oct 15, 2008 09:22 AM
- Cleveland BioLabs to Present at Maxim Group Growth Conference
Sep 29, 2008 08:30 AM
- Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day
Sep 23, 2008 08:30 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
CBLI
|
Compare to S&P
|
| YTD |
-78.86 %
|
-65.37 %
|
| 4 Weeks |
-39.02 %
|
-34.08 %
|
| 12 Weeks |
-62.04 %
|
-47.38 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 9.09 %
|
|
EPS Growth in Last Year: 53.12 %
|
|
Sales Growth in Last Quarter: 174.48 %
|
|
Sales Growth in Last Quarter: 179.88 %
|
|
|
